RT Journal Article
SR Electronic
T1 Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.28.22273040
DO 10.1101/2022.03.28.22273040
A1 Butler-Laporte, Guillaume
A1 Povysil, Gundula
A1 Kosmicki, Jack A.
A1 Cirulli, Elizabeth T
A1 Drivas, Theodore
A1 Furini, Simone
A1 Saad, Chadi
A1 Schmidt, Axel
A1 Olszewski, Pawel
A1 Korotko, Urszula
A1 Quinodoz, Mathieu
A1 Çelik, Elifnaz
A1 Kundu, Kousik
A1 Walter, Klaudia
A1 Jung, Junghyung
A1 Stockwell, Amy D
A1 Sloofman, Laura G
A1 Jordan, Daniel M.
A1 Thompson, Ryan C.
A1 Valle, Diane Del
A1 Simons, Nicole
A1 Cheng, Esther
A1 Sebra, Robert
A1 Schadt, Eric E.
A1 Schulze-Kim, Seunghee
A1 Gnjatic, Sacha
A1 Merad, Miriam
A1 Buxbaum, Joseph D.
A1 Beckmann, Noam D.
A1 Charney, Alexander W.
A1 Przychodzen, Bartlomiej
A1 Chang, Timothy
A1 Pottinger, Tess D
A1 Shang, Ning
A1 Brand, Fabian
A1 Fava, Francesca
A1 Mari, Francesca
A1 Chwialkowska, Karolina
A1 Niemira, Magdalena
A1 Pula, Szymon
A1 Baillie, J Kenneth
A1 Stuckey, Alex
A1 Salas, Antonio
A1 Bello, Xabier
A1 Pardo-Seco, Jacobo
A1 Gómez-Carballa, Alberto
A1 Rivero-Calle, Irene
A1 Martinón-Torres, Federico
A1 Ganna, Andrea
A1 Karczewski, Konrad J
A1 Veerapen, Kumar
A1 Bourgey, Mathieu
A1 Bourque, Guillaume
A1 Eveleigh, Robert JM
A1 Forgetta, Vincenzo
A1 Morrison, David
A1 Langlais, David
A1 Lathrop, Mark
A1 Mooser, Vincent
A1 Nakanishi, Tomoko
A1 Frithiof, Robert
A1 Hultström, Michael
A1 Lipcsey, Miklos
A1 Marincevic-Zuniga, Yanara
A1 Nordlund, Jessica
A1 Schiabor Barrett, Kelly M.
A1 Lee, William
A1 Bolze, Alexandre
A1 White, Simon
A1 Riffle, Stephen
A1 Tanudjaja, Francisco
A1 Sandoval, Efren
A1 Neveux, Iva
A1 Dabe, Shaun
A1 Casadei, Nicolas
A1 Motameny, Susanne
A1 Alaamery, Manal
A1 Massadeh, Salam
A1 Aljawini, Nora
A1 Almutairi, Mansour S.
A1 Arabi, Yaseen M.
A1 Alqahtan, Saleh A.
A1 Harthi, Fawz S. Al
A1 Almutairi, Amal
A1 Alqubaishi, Fatima
A1 Alotaibi, Sarah
A1 Binowayn, Albandari
A1 Alsolm, Ebtehal A.
A1 Bardisy, Hadeel El
A1 Fawzy, Mohammad
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 Geschwind, Daniel H
A1 Arteaga, Stephanie
A1 Stephens, Alexis
A1 Butte, Manish J.
A1 Boutros, Paul C.
A1 Yamaguchi, Takafumi N.
A1 Tao, Shu
A1 Eng, Stefan
A1 Sanders, Timothy
A1 Tung, Paul J.
A1 Broudy, Michael E.
A1 Pan, Yu
A1 Gonzalez, Alfredo
A1 Chavan, Nikhil
A1 Johnson, Ruth
A1 Pasaniuc, Bogdan
A1 Yaspan, Brian
A1 Smieszek, Sandra
A1 Rivolta, Carlo
A1 Bibert, Stephanie
A1 Bochud, Pierre-Yves
A1 Dabrowski, Maciej
A1 Zawadzki, Pawel
A1 Sypniewski, Mateusz
A1 Kaja, Elżbieta
A1 Chariyavilaskul, Pajaree
A1 Nilaratanakul, Voraphoj
A1 Hirankarn, Nattiya
A1 Shotelersuk, Vorasuk
A1 Pongpanich, Monnat
A1 Phokaew, Chureerat
A1 Chetruengchai, Wanna
A1 Tokunaga, Katsuhi
A1 Sugiyama, Masaya
A1 Kawai, Yosuke
A1 Hasegawa, Takanori
A1 Naito, Tatsuhiko
A1 Namkoong, Ho
A1 Edahiro, Ryuya
A1 Kimura, Akinori
A1 Ogawa, Seishi
A1 Kanai, Takanori
A1 Fukunaga, Koichi
A1 Okada, Yukinori
A1 Imoto, Seiya
A1 Miyano, Satoru
A1 Mangul, Serghei
A1 Abedalthagafi, Malak S
A1 Zeberg, Hugo
A1 Grzymski, Joseph J
A1 Washington, Nicole L
A1 Ossowski, Stephan
A1 Ludwig, Kerstin U
A1 Schulte, Eva C
A1 Riess, Olaf
A1 Moniuszko, Marcin
A1 Kwasniewski, Miroslaw
A1 Mbarek, Hamdi
A1 Ismail, Said I
A1 Verma, Anurag
A1 Goldstein, David B
A1 Kiryluk, Krzysztof
A1 Renieri, Alessandra
A1 Ferreira, Manuel A.R.
A1 Richards, J Brent
YR 2022
UL http://medrxiv.org/content/early/2022/07/20/2022.03.28.22273040.abstract
AB Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41×10−7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.Author Summary COVID-19 clinical outcomes vary immensely, but a patient’s genetic make-up is an important determinant of how they will fare against the virus. While many genetic variants commonly found in the populations were previously found to be contributing to more severe disease by the COVID-19 Host Genetics Initiative, it isn’t clear if more rare variants found in less individuals could also play a role. This is important because genetic variants with the largest impact on COVID-19 severity are expected to be rarely found in the population, and these rare variants require different technologies to be studies (usually whole-exome or whole-genome sequencing). Here, we combined sequencing results from 21 cohorts across 12 countries to perform a rare variant association study. In an analysis comprising 5,085 participants with severe COVID-19 and 571,737 controls, we found that the gene for toll-like receptor 7 (TLR7) on chromosome X was an important determinant of severe COVID-19. Importantly, despite being found on a sex chromosome, this observation was consistent across both sexes.Competing Interest StatementSee Suppl. Table 2.Funding StatementSee Suppl. Tables 2-4.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:See Suppl. Table 1-2.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe exome-wide burden test summary statistics are available in the Supplements. The single variant association studies summary statistics will be made available openly on the GWAS Catalog following publication.